MEDVi Tirzepatide vs Semaglutide: Which GLP-1 Should You Choose for Weight Loss?

What Does the Research Actually Say? (The Head-to-Head Data)

This isn't about marketing claims or influencer anecdotes. There's now a gold-standard head-to-head clinical trial directly comparing these two medications. Let's look at what it found.

The SURMOUNT-5 Trial: The Definitive Comparison

Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 is the first and only randomized clinical trial that directly compared tirzepatide to semaglutide for obesity. Here are the facts:

Trial design: 751 adults with obesity (BMI ≥30, or ≥27 with comorbidities) but without type 2 diabetes were randomized 1:1 across 32 sites in the U.S. and Puerto Rico. Participants received the maximum tolerated dose of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) weekly for 72 weeks. Both groups received counseling on diet and physical activity.

Source: Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1). DOI: 10.1056/NEJMoa2416394

What this means in real terms: A 200-pound person on tirzepatide could expect to lose roughly 40 pounds over 72 weeks. On semaglutide, roughly 27 pounds. That's a meaningful difference — but it's not the whole story.

Important Context Most Pages Won't Tell You

What About the Other Major Trials?

The bottom line from the research: tirzepatide produces more weight loss. Semaglutide has more long-term safety data and proven heart benefits. Both are dramatically effective compared to anything else available.

How Do Tirzepatide and Semaglutide Actually Work?

You don't need a pharmacology degree, but understanding the basic mechanism helps explain why tirzepatide produces more weight loss — and why semaglutide might still be the better choice for certain people.

*Illustration only. Simplified mechanism comparison for educational purposes.*

Semaglutide: One Hormone, One Pathway

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut naturally produces called glucagon-like peptide-1 (GLP-1). When you inject semaglutide once a week, it:

• Slows gastric emptying — food sits in your stomach longer, so you feel full after smaller meals
• Reduces appetite signals in the brain — the “I need to eat” noise gets quieter
• Enhances insulin secretion (glucose-dependent) — helps regulate blood sugar

Brand names: Wegovy (weight loss), Ozempic (type 2 diabetes), Rybelsus (oral, diabetes). Same molecule, different doses and approved uses.

Tirzepatide: Two Hormones, Two Pathways

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It does everything semaglutide does plus activates a second receptor — the glucose-dependent insulinotropic polypeptide (GIP) receptor. That additional pathway appears to:

• Enhance fat metabolism beyond what GLP-1 achieves alone
• Improve insulin sensitivity through a complementary mechanism
• Further suppress appetite via additional signaling

Think of it this way: semaglutide turns one dial. Tirzepatide turns two. Both get results — tirzepatide just has more levers to pull.

Brand names: Zepbound (weight loss, obstructive sleep apnea), Mounjaro (type 2 diabetes).

Why This Matters for Your Decision

The dual mechanism is why tirzepatide consistently outperforms semaglutide in trials. But “more powerful” doesn't automatically mean “better for you.” Some people respond beautifully to semaglutide and don't need the second pathway. Others need the additional push. Your body, your goals, and your budget determine which approach makes sense.

How Much Does Each Medication Cost Through MEDVi?

Cost is usually the deciding factor. Let's be completely transparent about what you'll actually pay.

*Illustration only. Pricing context for educational purposes. Always verify current pricing at medvi.org.*

MEDVi Pricing Breakdown (Verified February 2026)

Source: Pricing from medvi.org, verified February 2026. Semaglutide refills are stated as “locked” at $299; tirzepatide ongoing costs may vary by dose — confirm before enrolling. First month is promotional. Always confirm current pricing before enrolling.

What's Included in Every MEDVi Plan

Your monthly fee covers:

• Licensed physician evaluation through the OpenLoop Health network
• Personalized treatment plan and metabolic analysis report
• Monthly medication supply shipped to your door
• 24/7 messaging with your care team
• Unlimited appointments and dose adjustments
• No hidden membership fees

The Real Math: Is Tirzepatide's Premium Worth It?

Tirzepatide costs more per month than semaglutide through MEDVi — the exact difference depends on your dose level and should be confirmed before enrolling. Based on third-party review sites, tirzepatide refills may run roughly $100–$200 more per month than semaglutide's $299 refill price.

Here's one way to think about the value: for a 200-pound person, tirzepatide's additional efficacy (based on SURMOUNT-5) translates to roughly 12–14 extra pounds lost over a year. That works out to approximately $100–$170 per additional pound lost.

Is that worth it? That depends entirely on you. If losing an extra 12–14 pounds changes your health trajectory — coming off a medication, resolving sleep apnea, fitting into your life differently — the premium may pay for itself. If semaglutide's results would already get you where you need to be, save the money.

How MEDVi Compares to Brand-Name Pricing

Brand-name GLP-1 pricing has changed fast. Here's what the landscape looks like now:

Sources: Novo Nordisk press release, Nov 2025 (NovoCare pricing); Lilly pricing page (pricinginfo.lilly.com). Cash-pay programs have eligibility requirements and may change.

What Happens After the Introductory Price?

This is where most review sites get vague. Here's what we know:

• MEDVi's semaglutide injection refills are listed at $299/month (MEDVi states this is “locked” pricing).
• Tirzepatide injection refill pricing is not clearly published on MEDVi's main pages — third-party reviews cite $399–$499/month depending on dose, but confirm your specific refill cost with MEDVi support before enrolling.
• Get month-2+ pricing in writing before you commit. The $349 tirzepatide intro price is at a starting dose. Your ongoing cost may differ as your provider adjusts dosing.
• There are no long-term contracts. You pay month to month.

What Are the Side Effects? (Tirzepatide vs Semaglutide)

Let's address the elephant in the room. Both medications can make you feel lousy for the first couple of weeks — primarily nausea. Here's what to expect and how the two compare.

*Illustration only. Side effect information for educational purposes. Consult your provider for medical advice.*

Side Effects Both Medications Share

These are GLP-1 class effects, meaning you'll likely experience them regardless of which medication you choose:

• Nausea — the most common complaint, typically worst during weeks 1–2 and after each dose increase
• Diarrhea — usually mild and temporary
• Vomiting — less common than nausea, but possible
• Constipation — eating less means less moving through your system
• Abdominal discomfort — cramping or bloating, especially early on
• Decreased appetite — technically the therapeutic effect, but it can feel strange at first
• Injection site reactions — minor redness or itching, resolves quickly

For most people, these side effects peak during dose titration (the period when your provider gradually increases your dose) and fade within 2–4 weeks at each new level.

How SURMOUNT-5 Compared Their Safety Profiles

Here's something that surprises most people: in the head-to-head trial, tirzepatide actually had fewer patients drop out from GI side effects than semaglutide (2.7% vs 5.6%). The most common adverse events in both groups were gastrointestinal and were mostly mild-to-moderate in severity, occurring mainly during dose escalation. The overall safety profiles were comparable between the two medications.

The takeaway: neither medication is dramatically “worse” for side effects. Individual responses vary enormously — some people breeze through with minimal nausea, others have a rough first week or two regardless of which drug they're on.

Serious Risks to Know About (Both Medications)

These come directly from the FDA prescribing information for Wegovy and Zepbound and apply to anyone considering GLP-1 therapy:

Practical Tips for Managing Side Effects

These come from real MEDVi patient experiences and general clinical guidance:

1. Start low, go slow. Your provider will titrate your dose gradually — this is critical for minimizing nausea.
2. Drink more water than you think you need. GLP-1s slow digestion. Dehydration makes every side effect worse.
3. Eat small, bland meals during the first week at each new dose. Think crackers, rice, broth, bananas.
4. Add fiber intentionally. You're eating less, which means less intestinal bulk. Fiber helps keep things moving.
5. Don't skip doses, but don't push through dangerous symptoms either. If vomiting is severe or persistent, contact your MEDVi provider immediately.

For more help managing GLP-1 side effects, try our GLP-1 SOS side effect relief tool.

Tirzepatide vs Semaglutide Dosage Chart

One of the most-searched questions — and one that's often answered poorly. Here's the clear picture.

Semaglutide (Wegovy) Dosing for Weight Loss

Tirzepatide (Zepbound) Dosing for Weight Loss

Source: FDA prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide). Your MEDVi provider will determine your specific dosing schedule based on your response and tolerance.

Is There an Equivalent Dose Between the Two?

No. There is no FDA-approved milligram-to-milligram conversion between tirzepatide and semaglutide. They're different molecules acting on different receptor combinations at different potencies. Anyone who gives you a simple conversion chart is guessing.

If you're switching from one to the other through MEDVi, your provider will typically restart the titration process at a lower dose of the new medication and ramp up gradually. This minimizes side effects during the transition. For a detailed dosing reference, see our tirzepatide dosing schedule guide.

How Long Until You See Results?

Based on clinical trial data and patient reports:

• Weeks 1–4: Appetite reduction is usually noticeable within the first week. Scale changes may be minimal — your body is adjusting.
• Weeks 4–8: Most patients begin seeing consistent weight loss of 1–2 lbs per week.
• Months 3–6: This is typically where momentum builds. You've reached or are approaching maintenance dose, and the weight loss becomes more pronounced.
• Months 6–18: Continued steady loss. Peak results in most clinical trials occur around the 68–72 week mark.

Can You Switch Between Semaglutide and Tirzepatide on MEDVi?

Yes — and this flexibility is one of the genuine advantages of MEDVi's platform. You're not locked into a single medication.

Semaglutide → Tirzepatide

This is the most common switch. If you start with semaglutide and your weight loss stalls after reaching maintenance dose (typically 3–4 months in), you can request a switch to tirzepatide. Your MEDVi provider will design a new titration schedule. Expect a brief adjustment period as your body adapts to the dual-receptor mechanism.

Tirzepatide → Semaglutide

Less common, but it happens. Some patients switch to semaglutide after reaching their goal weight — using the lower-cost medication for maintenance rather than aggressive loss. Others switch if tirzepatide's side effects don't settle.

The Practical Strategy

Brand-Name vs Compounded GLP-1: What MEDVi Users Need to Know (2026 Update)

This is the section most affiliate sites skip. We're not going to.

What “Compounded” Means

When MEDVi prescribes compounded semaglutide or tirzepatide, the medication is made by a licensed compounding pharmacy (MEDVi partners with Belmar Pharma Solutions) rather than by the original manufacturers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide). The compounded version contains the same active pharmaceutical ingredient, but:

• It has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality
• It may differ from the brand-name product in formulation, concentration, or inactive ingredients
• It is not an FDA-approved medication

This is the honest reality. We're not going to sugarcoat it. For a deeper look at compounded medication safety, see our compounded semaglutide safety guide.

Why Compounded GLP-1s Exist

Brand-name Wegovy has a list price of roughly $1,349/month, though Novo Nordisk now offers it at $349/month for self-pay patients through NovoCare Pharmacy. Zepbound's list price is around $1,086/month, with Lilly offering self-pay savings programs as well. Even with these reductions, many Americans face insurance barriers — most plans don't cover GLP-1s for weight loss, or require extensive prior authorizations. For patients who can't access affordable brand-name coverage, compounded medications offer an alternative path.

During the 2023–2024 GLP-1 shortage, the FDA temporarily allowed compounding pharmacies to produce copies of these medications. That shortage has since been resolved — the FDA removed both semaglutide and tirzepatide from its drug shortage list — and the regulatory landscape has shifted significantly.

The 2026 FDA Landscape

Here's what's happened recently:

• December 2024: FDA determined the tirzepatide shortage was resolved.
• February–May 2025: Enforcement discretion periods for compounding pharmacies ended (503A and 503B facilities).
• May 2025: A federal court upheld FDA's determination that tirzepatide was no longer in shortage.
• September 2025: FDA issued warning letters to numerous GLP-1 compounders and manufacturers regarding claims the FDA considered false or misleading.
• February 2026: FDA announced its intention to take further enforcement action against non-FDA-approved compounded GLP-1 products.

The regulatory environment is tightening. Compounded GLP-1 medications remain available through licensed pharmacies in many states, but this landscape is evolving. MEDVi continues to operate through licensed compounding pharmacy partners.

How MEDVi Mitigates These Concerns

• MEDVi is LegitScript certified — independently monitored for compliance with applicable state and federal laws
• Their primary pharmacy partner, Belmar Pharma Solutions, is a nationally recognized, licensed compounding pharmacy
• Every prescription goes through a licensed physician via the OpenLoop Health network
• Patients get 24/7 access to clinical support for side effect management and dosing questions

Our Safe Provider Checklist

If you're considering any telehealth GLP-1 program (MEDVi or otherwise), verify these before enrolling:

Is MEDVi Legit? How the Program Actually Works

Fair question. Let's walk through what actually happens when you sign up.

Step 1: Online Health Assessment (5–10 minutes)

You complete a detailed questionnaire covering your medical history, current medications, weight loss goals, and BMI. This isn't a rubber stamp — MEDVi uses exclusionary criteria developed by their clinical partner (OpenLoop Health) to determine if GLP-1 therapy is appropriate for you. Not everyone qualifies.

Step 2: Physician Review (Usually Within 24 Hours)

A US-licensed provider reviews your assessment. If medically necessary, lab work may be requested. Some states require a video consultation due to telehealth laws.

Step 3: Prescription + Shipping (3–5 Business Days)

If approved, your provider prescribes either semaglutide or tirzepatide based on your clinical profile. You can express a preference, but the final decision is the clinician's. Medication ships from the pharmacy directly to your door in discreet packaging.

Step 4: Ongoing Support

This is where MEDVi differentiates from bare-bones telehealth operations. Your plan includes:

• 24/7 messaging with your care team
• Unlimited video appointments
• Monthly check-ins and dose adjustments
• Metabolic analysis reporting

What MEDVi Is (and What It Isn't)

Per their own terms and conditions, MEDVi is a platform that connects patients with independent healthcare providers — it doesn't itself provide medical services. The prescribing clinicians are part of the OpenLoop Health network. This is a standard telehealth structure, similar to how Hims, Ro, and other platforms operate.

MEDVi has served over 100,000 patients, holds over 9,900 reviews on Trustpilot, and maintains a ConsumerAffairs presence with detailed patient feedback. It's a real, operating telehealth program — not a fly-by-night operation. For a deeper review, see our MEDVi tirzepatide review.

What Real MEDVi Patients Say

We pulled these from verified third-party review platforms. These are real people, unedited (except for length).

How to Cancel MEDVi (and What the Refund Policy Actually Says)

We believe a good review tells you how to leave, not just how to sign up. Here's MEDVi's cancellation and refund policy based on their published terms:

Cancellation

• MEDVi operates on a month-to-month basis with no long-term contract.
• To cancel, you must submit your request at least 72 hours before your next billing date.
• You can cancel by contacting MEDVi's support team via email or phone.

Refund Policy

• If your cancellation request is received before medication has been ordered for the current cycle, you may be eligible for a refund.
• If medication has already been ordered or shipped, refunds are generally not available for that cycle.
• MEDVi offers a weight loss guarantee: if you follow the program for at least 5 months and do not lose any weight, you may qualify for a refund minus 25% of consultation fees.

Source: MEDVi refund policy page at medvi.org. Terms may change — verify current policies before enrolling.

Is Semaglutide the Same as Ozempic? (Brand Name Confusion, Cleared Up)

This question pops up constantly, and the confusion is understandable. Here's the simple breakdown:

Semaglutide is the active ingredient — the actual molecule that does the work in your body. It's sold under three different brand names, each with different FDA-approved uses:

Key point: Using Ozempic for weight loss is off-label. Ozempic is FDA-approved only for type 2 diabetes. The semaglutide product approved for weight loss is Wegovy, which is dosed higher (2.4 mg vs Ozempic's max of 2.0 mg).

Similarly, tirzepatide is the active ingredient in:

What MEDVi prescribes: MEDVi primarily prescribes compounded semaglutide and tirzepatide — pharmacy-prepared formulations made by licensed compounding pharmacies. These are not the brand-name products and are not FDA-approved. MEDVi can also prescribe brand-name Ozempic, but at $1,999/month, most patients opt for compounded alternatives.

Why This Matters for You

If your doctor says “you should try semaglutide” and you go to MEDVi, you're getting compounded semaglutide — the same active molecule as Wegovy and Ozempic, made by a licensed compounding pharmacy, at a fraction of the brand-name cost. Same active ingredient, different manufacturer, different regulatory status.

When Should You Take Semaglutide or Tirzepatide? (Timing and Practical Tips)

Injection Timing

Both medications are taken once weekly. The FDA labeling recommends:

• Pick a consistent day each week (e.g., every Monday). Consistency helps you remember and keeps drug levels stable.
• You can inject any time of day — morning, afternoon, evening. Choose whatever fits your routine.
• Injection sites: Abdomen, thigh, or upper arm. Rotate sites each week to avoid irritation.
• If you miss a dose: Take it as soon as you remember if it's within a few days of the missed dose. If your next scheduled dose is coming up soon, skip the missed one and resume your regular schedule. Never double up.

Food Timing and Nausea Management

This is where practical wisdom from real patients matters more than label language:

• Don't eat a huge meal right before or after injection. Some patients find that injecting in the evening (so any initial nausea hits while they're sleeping) works well.
• For the first week at each new dose: Stick to smaller, blander meals. Think grilled chicken and rice, not a double cheeseburger.
• Hydration is everything. GLP-1 medications slow gastric emptying, which can cause constipation and make dehydration symptoms worse. Aim for at least 64 oz of water daily.
• Protein first. Since you'll be eating less overall, make every bite count. Prioritize protein to preserve muscle mass during weight loss. Many MEDVi patients report that hitting 80–100g of protein daily helps maintain energy and results.

Tablet Timing (If You Choose the Oral Option)

MEDVi offers compounded semaglutide and tirzepatide in daily dissolvable tablet form. If you go this route:

• Take on an empty stomach
• Wait at least 30 minutes before eating or drinking anything other than a small sip of water
• Consistency matters — take it at the same time each day

One thing to know: clinical evidence generally shows injectable GLP-1s produce more weight loss than oral formulations. If maximizing results is your priority, injections are the stronger choice. If needle phobia is a genuine barrier, tablets are far better than not starting at all.

What Happens If You Stop Taking GLP-1 Medication?

This is something every patient should understand before starting.

The Clinical Reality

GLP-1 medications treat the underlying biology of obesity — they don't “cure” it. When you stop the medication, the hormonal signals that suppress appetite and regulate metabolism return to their pre-treatment state. Multiple studies have shown significant weight regain after discontinuation.

In the STEP-1 trial extension study, participants who stopped semaglutide regained roughly two-thirds of their lost weight within a year of stopping. Tirzepatide follow-up data shows similar patterns.

What This Means for Your Planning

This isn't a “take it for 6 months and you're fixed” situation. For most patients, GLP-1 therapy is a long-term (potentially lifelong) commitment — similar to how blood pressure medication manages hypertension.

Practical approaches MEDVi patients use:

1. Long-term maintenance dosing: Stay on a lower maintenance dose indefinitely. This is the most evidence-supported approach for keeping weight off.
2. Start with tirzepatide for aggressive loss, then switch to semaglutide for cheaper maintenance. Some patients use the more powerful (and more expensive) medication to reach their goal, then transition to semaglutide for long-term management at a lower monthly cost.
3. Lifestyle foundation building during treatment. Use the appetite suppression window to build exercise habits, learn portion control, and develop a sustainable relationship with food.
4. Discuss a tapering plan with your provider rather than abruptly stopping. Gradual dose reduction may ease the transition.

The honest truth: stopping GLP-1 medication without a robust maintenance strategy usually means regaining weight. That's not a failure of willpower — it's biology. Factor ongoing medication into your long-term budget planning from the beginning.

Your 5-Step Action Plan

You've done the research. Here's how to move forward without overthinking it.

The Verdict: Start Here

You've read the data. You've seen the pricing. You know the trade-offs. Here's where it lands:

*Illustration only. Decision summary for educational purposes.*

For most people starting GLP-1 therapy: begin with MEDVi's compounded semaglutide at $179 for month one. It's backed by strong clinical research on the FDA-approved version, dramatically more affordable, and leaves the door open to upgrade later. You don't need to spend more on day one to get transformative results. Semaglutide has helped millions of people lose significant weight — in the STEP-1 trial, participants lost nearly 15% of their body weight on average. That's 30 pounds for someone starting at 200. That's life-changing for most people, and it's the more affordable option.

For people who need maximum weight loss or have already tried semaglutide: tirzepatide through MEDVi is the strongest tool available. The SURMOUNT-5 data published in the New England Journal of Medicine speaks for itself — 20.2% average body weight loss, 47% more than semaglutide, with participants losing an average of 50.3 pounds. If your goals are aggressive, your budget supports $399–$499/month ongoing, and you want every advantage the science currently offers, this is the evidence-backed choice.

Frequently Asked Questions: MEDVi Tirzepatide vs Semaglutide

How We Researched This Page

Transparency matters — especially for a YMYL (Your Money or Your Life) topic like weight loss medication. Here's exactly how we built this comparison:

• Clinical evidence: Our primary source is the SURMOUNT-5 trial published in the New England Journal of Medicine (May 2025), the only head-to-head comparison of tirzepatide vs semaglutide for obesity. We also reference the STEP-1 trial (semaglutide vs placebo, NEJM 2021), SURMOUNT-1 trial (tirzepatide vs placebo, NEJM 2022), and the SELECT cardiovascular outcomes trial for supporting context. All trial citations include DOI numbers for independent verification.
• Pricing verification: All MEDVi pricing was checked directly at medvi.org in February 2026. We re-verify monthly and update this page accordingly. Brand-name pricing references are sourced from manufacturer pricing pages.
• FDA sources: Side effect profiles, boxed warnings, and contraindications come from the official FDA prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide). Compounding regulation information comes from FDA.gov press announcements and enforcement reports.
• Patient experiences: Testimonials are sourced from ConsumerAffairs and Trustpilot — third-party, verified review platforms. We do not fabricate or modify patient quotes.
• What we don't do: We're not doctors. This page is not medical advice. We don't claim to have personally tested every medication option. We don't hide our affiliate relationship with MEDVi. And we don't pretend compounded medication is identical to FDA-approved products.

Our commitment: This page is reviewed and updated monthly. If you find an error or outdated information, contact us. Getting it right matters more than getting traffic.

Sources & References

1. Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025;393(1). DOI: 10.1056/NEJMoa2416394. PubMed
2. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. (STEP-1 trial)
3. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(4):327-340. (SURMOUNT-1 trial)
4. FDA Prescribing Information: Wegovy (semaglutide). accessdata.fda.gov
5. FDA Prescribing Information: Zepbound (tirzepatide). accessdata.fda.gov
6. FDA: “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” fda.gov
7. Eli Lilly: SURMOUNT-5 Results Press Release. investor.lilly.com
8. American College of Cardiology: SURMOUNT-5 Analysis. acc.org
9. MEDVi Official Website. medvi.org
10. MEDVi Policy Pages: Pricing, Refund, Terms. medvi.org
11. ConsumerAffairs: MEDVi Reviews. consumeraffairs.com
12. Trustpilot: MEDVi Reviews. trustpilot.com